SHH and medulloblastoma: SHH pathway inhibitors, such as sonidegib, are being assessed in clinical trials for adult medulloblastoma, and the European trial EORTC 1634-BTG/NOA-23 is currently evaluating sonidegib as an adjunct to standard chemoradiotherapy in post-pubertal patients with SHH-active disease [21].